Sebia

Founded in 1967, Sebia is a global specialized In Vitro Diagnostic player providing equipment and reagents for the screening and monitoring of various diseases, primarily in the areas of Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathy, Autoimmune & Infectious diseases and other rare pathologies.

Following the recent acquisitions of ORGENTEC, Corgenix (2021) and ZEUS Scientific (2022), Sebia now develops and markets solutions for autoimmunity diagnostics.

Our mission is to provide powerful tools that translate what’s happening in patients’ bodies into a clear, concise and interpretable language.

We call it our new language of life. It makes it easier to understand, diagnose and treat chronic and metabolic diseases. Cancer, obesity, aging and depression share a common biology: they are metabolic and inflammatory. Those pathological imbalances lead to protein modification which require special separation techniques to give us a better understanding. Capillary Electrophoresis (CE) is the most accurate and efficient method of separation to unlock these complex conditions.

Headquartered in the South of Paris (Lisses, France), We set high standards in making continuous advances in technologies, scientific excellence and manufacturing capabilities, providing Sebia the possibility to pursue diagnostic solutions with an exciting pipeline of new tests and automated equipment.